Astrana Health, Inc. Delivers Record 2025 Results, Expands Buyback, and Issues Robust 2026 Guidance

Key Financial Highlights and Strategic Updates for Investors

Astrana Health, Inc. (NASDAQ: ASTH), a physician-centric, AI-powered, risk-bearing healthcare management company, has announced its consolidated financial results for the fourth quarter and full year ended December 31, 2025. The company also provided guidance for 2026, updated shareholders on acquisition integration and internal control issues, and revealed an expansion of its share repurchase program.

Highlights of the 2025 Financial Results

• Total 2025 Revenue: \$3.18 billion, up 56% year-over-year, reaching the upper end of prior guidance.
• Adjusted EBITDA: \$205.4 million, up 21% year-over-year.
• Net Income Attributable to Astrana: \$22.5 million.
• Diluted EPS: \$0.46.
• Free Cash Flow: \$104.5 million, more than doubling from the prior year.
• Q4 2025 Revenue: \$950.5 million (up 43% year-over-year); Q4 Adjusted EBITDA \$52.5 million (up 50%).
• Adjusted EPS (Year): \$2.20; Adjusted EPS (Q4): \$0.54.
• Care Partners Revenue: \$3.02 billion, up 55% year-over-year.

Operational and Strategic Milestones

• Prospect Health Acquisition Integration: Ahead of schedule, supporting growth in revenue and EBITDA.
• Expansion of Share Repurchase Program: The Board increased buyback authorization from \$50 million to \$100 million. As of December 31, 2025, \$35.9 million remained available for repurchases. In Q4 2025, 633,844 shares were repurchased.
• Strengthened Balance Sheet: Cash and cash equivalents increased to \$429.5 million from \$288.5 million a year ago. Total assets rose to \$2.22 billion from \$1.35 billion.
• Leverage: Long-term debt increased to \$990.9 million from \$425.3 million, reflecting acquisition activity and growth investments.

2026 Guidance: Significant Growth Expected

• Full-Year 2026 Revenue Guidance: \$3.8 billion to \$4.1 billion (approx. 24% growth YoY at midpoint).
• Adjusted EBITDA Guidance for 2026: \$250 million to \$280 million (approx. 29% growth YoY at midpoint).
• Q1 2026 Revenue Guidance: \$900 million to \$1 billion; Adjusted EBITDA: \$60 million to \$70 million.

Management expressed confidence in achieving these targets, citing strong physician alignment, a scalable technology-enabled clinical infrastructure, and the successful Prospect Health integration as key drivers.

Update on Annual Report Filing and Internal Controls

• Delayed 10-K Filing: Astrana will file a Form 12b-25 with the SEC to extend the deadline for its Annual Report on Form 10-K for 2025 due to a material weakness in internal controls over financial reporting, primarily related to acquisition and purchase accounting processes.
• No Material Misstatement: The company emphasizes that this issue does not reflect a material misstatement of financial results and does not require restatements of historical periods. Astrana expects to file the 10-K within the 15-day extension period and is making targeted investments to remediate the issue.

Segment Performance (2025)

• Care Partners Segment: Revenue up 55% year-over-year to \$3.02 billion; income from operations up 10%.
• Care Delivery Segment: Revenue up 83% to \$250.7 million.
• Care Enablement Segment: Revenue up 59% to \$246.7 million.

Shareholder-Relevant Issues and Potential Price-Moving News

• Record Results and Strong Guidance: Astrana’s robust revenue and earnings growth, along with bullish 2026 guidance, could drive investor optimism and share price appreciation.
• Buyback Expansion: Doubling the buyback program to \$100 million signals management’s confidence in the company’s intrinsic value and could support the stock price.
• Internal Controls Weakness and 10-K Delay: While not expected to impact reported results, the disclosure of a material weakness in internal controls related to acquisitions and the delayed 10-K filing may create near-term uncertainty or volatility. However, management’s proactive remediation efforts and assurance of no material misstatements may mitigate market concerns.
• Significant Acquisition Integration: Successful ahead-of-schedule integration of Prospect Health could drive incremental upside if operational synergies are realized.
• Leverage and Growth: The increase in long-term debt is notable, but is paired with substantial asset growth and free cash flow generation, suggesting balance sheet strength is being maintained.

Company Overview and Outlook

Astrana Health supports over 20,000 providers and 1.6 million patients, leveraging a proprietary technology platform and aligned provider networks to deliver value-based care at scale. Management remains focused on disciplined risk management, technology-driven clinical infrastructure, and continued expansion. The company is positioning itself for sustainable growth, improved patient outcomes, and greater shareholder value.

Disclaimer: This article is based on Astrana Health, Inc.’s official earnings release and related financial materials. Forward-looking statements are subject to risks and uncertainties. Investors should review all official filings and disclosures before making investment decisions. This summary is for informational purposes only and does not constitute investment advice.

View Astrana Health, Inc. Historical chart here